- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05822284
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
April 18, 2023 updated by: Liu Wenliang, Second Xiangya Hospital of Central South University
The Role of Dynamic Circulating Tumor DNA-Molecular Residual Disease (ctDNA-MRD) Testing in Stage IIIB-C Oncogene-negative NSCLC Patients Treated With Induction Chemoimmunotherapy in the Multidisciplinary Team (MDT) Model of Diagnosis and Treatment
The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage IIIB-C driver-negative NSCLC in the MDT model, so as to accurately guide clinical diagnosis and treatment.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a single-center, observational, non-interventional, prospective study.
50 patients diagnosed with stage IIIB-C driver-negative NSCLC receiving induction chemoimmunotherapy will be planned to be enrolled in the study.
Pre-treatment biopsy tissues of enrolled patients will be collected for next-generation sequencing (NGS) of institutionally-developed 1021-gene panel, and personalized detection panel will be customized based on NGS testing results.
Patients will be received induction chemoimmunotherapy followed by surgery or non-surgical treatment in the MDT model and ctDNA-MRD testing will be performed at prespecified time points.
For patients who received surgery following induction therapy, peripheral blood will be collected in baseline, 1 day before the third cycle of neoadjuvant therapy, 1 day before surgery, 3 days after surgery and landmark time and pulmonary venous blood will be collected intraoperatively.
For patients who received non-surgical treatment following induction therapy, peripheral blood will be collected in baseline, 1 day before the third cycle of neoadjuvant therapy, 1 day before non-surgical therapy and landmark time.
All included patients will be regularly followed up for at least 5 years.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yan Hu, M.D., Ph.D.
- Phone Number: 8685296122
- Email: yanhu@csu.edu.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China
-
Contact:
- Yan Hu, M.D., Ph.D.
- Email: yanhu@csu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Potentially resectable stage IIIB-C driver-negative NSCLC patients receiving induction chemoimmunotherapy
Description
Inclusion Criteria:
- Histopathology or cytology confirmed the non-small cell lung cancer
- Age ranging from 18 to 75
- Agree to participate in this study and sign an informed consent form
- Treatment-naive tumor
- Driver gene negativity
- According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage IIIB-C potentially resectable tumor
- The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score is 0-1
Exclusion Criteria:
- Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
- Small cell lung cancer
- Driver gene positivity
- Tumor directly invades esophagus, heart, aorta, diaphragm, trachea, or carina, or is considered unresectable even following induction therapy
- Patients with solid organ or blood system transplantation
- Previous use of recombinant cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1), or programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors
- Patients with interstitial lung disease
- Patients with acute or chronic infectious disease
- Pregnant and lactating women
- Patients who have undergone other clinical drug trials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with stage IIIB-C driver-negative NSCLC receiving induction chemoimmunotherapy
|
NGS and ctDNA-MRD detection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predicting Progression Free Survival
Time Frame: up to 5 years
|
Ability of dynamic ctDNA-MRD assessment to predict progression-free survival (PFS) in stage IIIB-C driver-negative NSCLC patients receiving induction chemoimmunotherapy followed by surgery or non-surgical therapy
|
up to 5 years
|
Predicting pathologic complete response
Time Frame: Up to 1 year
|
Ability of dynamic ctDNA-MRD assessment to predict pathologic complete response (pCR) in stage IIIB-C driver-negative NSCLC patients receiving induction chemoimmunotherapy followed by surgery
|
Up to 1 year
|
Predicting Overall Survival
Time Frame: up to 5 years
|
Ability of dynamic ctDNA-MRD assessment to predict overall survival (OS) in stage IIIB-C driver-negative NSCLC patients receiving induction chemoimmunotherapy followed by surgery or non-surgical therapy
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate(ORR)
Time Frame: Up to 1 year
|
The proportion of patients achieved complete or partial remission according to RECIST 1.1 prior to definitive surgery.
|
Up to 1 year
|
Adverse events (AEs)
Time Frame: Up to 5 years
|
Number of patients experiencing AEs will be recorded.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to 5 years
|
Perioperative complications rate
Time Frame: Up to 3 years
|
Number of patients experiencing perioperative complications will be recorded.
|
Up to 3 years
|
Health-related Quality of Life
Time Frame: Up to 5 years
|
Health-related Quality of Life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0.
|
Up to 5 years
|
Perioperative pain evaluation
Time Frame: Up to 3 years
|
Perioperative pain evaluation assessed by a numeric rating scale (NRS).
A total of 11 points from 0 to 10 are used to describe the pain intensity.
0 means no pain, the number of points increases when the pain is stronger, and 10 means the most intense pain.
|
Up to 3 years
|
Lung cancer-related Quality of Life
Time Frame: Up to 5 years
|
Health-related Quality of Life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire in Lung Cancer.
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2023
Primary Completion (Anticipated)
March 1, 2029
Study Completion (Anticipated)
March 1, 2029
Study Registration Dates
First Submitted
April 4, 2023
First Submitted That Met QC Criteria
April 18, 2023
First Posted (Actual)
April 20, 2023
Study Record Updates
Last Update Posted (Actual)
April 20, 2023
Last Update Submitted That Met QC Criteria
April 18, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LYF2023026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
Clinical Trials on NGS and ctDNA-MRD detection
-
BAIYONG SHENGeneCast Biotechnology Co., Ltd.Not yet recruitingPancreatic Cancer ResectableChina
-
The First Hospital of Jilin UniversityGeneplus-Beijing Co. Ltd.Recruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversitySecond Affiliated Hospital of Xi'an Jiaotong UniversityNot yet recruiting
-
National Cancer Center, JapanRecruitingCervical Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Clear Cell CarcinomaJapan, Korea, Republic of, Malaysia, Thailand, Philippines, Singapore, Taiwan, Vietnam
-
WeiWei XiaoHaplox Biotechnology Co., Ltd.RecruitingMinimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant ChemoradiotherapyChina
-
AnchorDx Medical Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsActive, not recruiting
-
Lung Cancer Mutation ConsortiumLung Cancer Research FoundationRecruiting
-
Swiss Group for Clinical Cancer ResearchRecruitingNon-hodgkin Lymphoma, B CellSwitzerland
-
Shanghai Zhongshan HospitalFudan University; Amoy Diagnostics Co., LTDNot yet recruitingPatients With Non-metastatic Pancreatic Cancer | Evaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic AdenocarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen UniversityUnknownNon-small Cell Lung Cancer Stage IChina